Market research
OPNT Opiant Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 109M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- 0.0%
- Beta
- 0.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6837501039
- Market cap
- 109M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- 0.0%
- Beta
- 0.83
About
About Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OPNT discussion.
5 years, 4 months ago
Opiant Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 55.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Opiant Pharmaceuticals, Inc's total revenue rose by 29.4% to $10M since the same quarter in the previous year.
Its net income has dropped by 164.2% to $-686K since the same quarter in the previous year.
Finally, its free cash flow fell by 123.8% to $-2M since the same quarter in the previous year.
Based on the above factors, Opiant Pharmaceuticals, Inc gets an overall score of 3/5.